Replimune Net Income Per Share from 2010 to 2026
| REPL Stock | USD 7.03 0.36 4.87% |
Net Loss | First Reported 2010-12-31 | Previous Quarter (3.53) | Current Value (3.71) | Quarterly Volatility 1.30395775 |
Check Replimune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Replimune's main balance sheet or income statement drivers, such as Interest Income of 935.8 K, Depreciation And Amortization of 7.2 M or Interest Expense of 9.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.79. Replimune financial statements analysis is a perfect complement when working with Replimune Valuation or Volatility modules.
Replimune | Net Income Per Share | Build AI portfolio with Replimune Stock |
Historical Net Income Per Share data for Replimune serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Replimune Group represents a compelling investment opportunity.
Latest Replimune's Net Income Per Share Growth Pattern
Below is the plot of the Net Income Per Share of Replimune Group over the last few years. It is Replimune's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Replimune's overall financial position and show how it may be relating to other accounts over time.
| Net Income Per Share | 10 Years Trend |
|
Net Income Per Share |
| Timeline |
Replimune Net Income Per Share Regression Statistics
| Arithmetic Mean | (1.56) | |
| Coefficient Of Variation | (83.44) | |
| Mean Deviation | 1.13 | |
| Median | (1.33) | |
| Standard Deviation | 1.30 | |
| Sample Variance | 1.70 | |
| Range | 3.3518 | |
| R-Value | (0.95) | |
| Mean Square Error | 0.19 | |
| R-Squared | 0.89 | |
| Slope | (0.24) | |
| Total Sum of Squares | 27.20 |
Replimune Net Income Per Share History
About Replimune Financial Statements
Replimune investors utilize fundamental indicators, such as Net Income Per Share, to predict how Replimune Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | (3.53) | (3.71) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Replimune Correlation against competitors. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. Anticipated expansion of Replimune directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Replimune assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Replimune's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Replimune should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Replimune's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.